中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (2): 249-252.doi: 10.3969/j.issn.1673-8225.2011.02.014

• 组织构建与中医药 tissue construction and traditional Chinese medicine • 上一篇    下一篇

金乌骨通胶囊含药血清对成骨细胞骨保护素/核因子κB受体活化因子配体分泌的影响

刘春颖1，郑文奎2，祖金池2，周玉娟1，刘新霞1，刘  莉1，张  喆1   

  1. 1河北大学医学部药理教研室，河北省保定市  071000
    2河北大学附属医院骨科，河北省保定市 071000
  • 收稿日期:2010-07-09 修回日期:2010-09-27 出版日期:2011-01-08 发布日期:2011-01-08
  • 作者简介:刘春颖★，女，1977年生，河北省保定市人，汉族，硕士，讲师，主要从事骨科药理学方面的研究。 liuchy310@163. com
  • 基金资助:

    河北省中医药管理局科研计划项目(NO. 2009149)。

Effects of serum containing Jinwugutong capsule substances on secretion of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in osteoblasts 

Liu Chun-ying1, Zheng Wen-kui2, Zu Jin-chi2, Zhou Yu-juan1, Liu Xin-xia1, Liu Li1, Zhang Zhe1   

  1. 1Department of Pharmacology, Hebei University Health Science Center, Baoding  071000, Hebei Province, China
    2Deartment of Orthopaedics, Affiliated Hospital of Hebei University, Baoding  071000, Hebei Province, China
  • Received:2010-07-09 Revised:2010-09-27 Online:2011-01-08 Published:2011-01-08
  • About author:Liu Chun-ying★, Master, Lecturer, Department of Pharmacology, Hebei University Health Science Center, Baoding 071000, Hebei Province, China liuchy310@163.com
  • Supported by:

    the Science Research Item of Administration of Traditional Chinese Medicine in Hebei Province, No. 2009149

PDF

379

摘要：

背景：金乌骨通胶囊对绝经后骨质疏松症具有明显的治疗作用，但其具体的作用机制尚不清楚。
目的：观察金乌骨通胶囊含药血清对成骨细胞骨保护素、细胞核因子κB受体活化因子配体(receptor activator nuclear factor kappa B ligand，RANKL)表达的影响。
方法：切除雌性SD大鼠双侧卵巢制备去卵巢血清，灌胃给予去卵巢大鼠金乌骨通胶囊制备去卵巢含药血清。取第3代生长状况良好的出生24 h内的SD大鼠成骨细胞，正常血清组、去卵巢血清组、去卵巢含药血清组分别加入正常雌性SD大鼠血清、去卵巢血清和去卵巢含药血清培养72 h。采用酶联免疫吸附法检测成骨细胞骨保护素和RANKL的分泌水平。
结果与结论：与正常血清组比较，去卵巢血清组成骨细胞骨保护素的表达明显降低(P < 0.01)，而RANKL的表达明显升高(P < 0.05)；与去卵巢血清组比较，去卵巢含药血清组成骨细胞骨保护素的表达明显升高(P  < 0.05)，RANKL 的表达明显降低(P  < 0.05)。说明金乌骨通胶囊可通过增加成骨细胞骨保护素的表达，抑制RANKL的表达来实现治防治骨质疏松症的目的。

关键词: 金乌骨通胶囊, 含药血清, 成骨细胞, 破骨细胞, 骨保护素, 核因子&kappa, B受体活化因子配体

Abstract:

BACKGROUND: Jinwugutong capsule (JWGTC) has the evident therapeutic effect on postmenopausal osteoporosis, but the specific mechanism is unclear.
OBJECTIVE: To investigate the effects of serum containing JWGTC on expression of osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) in osteoblasts.
METHODS: Osteoporosis model was made in ovariotomy method. JWGTC was intragastric administrated into ovariectomized rats. The 3rd passage of osteoblast was harvested from 24-hour SD rats and cultured by normal serum, ovariectomized serum and JWGTC treated serum, respectively for 72 hours. ELASA method was used to detect the mRNA expression of osteoprotegerin and RANKL.
RESULTS AND CONCLUSION: Compared with the normal serum group, expression of osteoprotegerin in osteoblasts of the ovariectomized serum group decreased significantly (P < 0.01), while the RANKL expression increased remarkably (P < 0.05); compared with the ovariectomized serum group, expression of osteoprotegerin in osteoblasts of the JWGTC treated serum was increased (P < 0.05), while the expression of RANKL decreased (P < 0.05). JWGTC can prevent and treat osteoporosis by increasing the expression of osteoprotegerin and inhibiting the mRNA expression of RANKL.

中图分类号: